LABS vs. MDP, TGOD, NINE, SUGR, WMD, HEXO, VIR, ZOM, IN, and META
Should you be buying MediPharm Labs stock or one of its competitors? The main competitors of MediPharm Labs include Medexus Pharmaceuticals (MDP), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), SugarBud Craft Growers (SUGR), WeedMD (WMD), HEXO (HEXO), Viridium Pacific Group (VIR), Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM), InMed Pharmaceuticals (IN), and Meta Growth (META). These companies are all part of the "drug manufacturers - specialty & generic" industry.
MediPharm Labs vs.
Medexus Pharmaceuticals (TSE:MDP) and MediPharm Labs (TSE:LABS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability, community ranking and earnings.
Medexus Pharmaceuticals has a beta of 1.96, suggesting that its share price is 96% more volatile than the S&P 500. Comparatively, MediPharm Labs has a beta of 0.88, suggesting that its share price is 12% less volatile than the S&P 500.
Medexus Pharmaceuticals has a net margin of 1.00% compared to MediPharm Labs' net margin of -35.25%. Medexus Pharmaceuticals' return on equity of 3.95% beat MediPharm Labs' return on equity.
MediPharm Labs received 16 more outperform votes than Medexus Pharmaceuticals when rated by MarketBeat users. However, 90.00% of users gave Medexus Pharmaceuticals an outperform vote while only 65.79% of users gave MediPharm Labs an outperform vote.
Medexus Pharmaceuticals presently has a consensus target price of C$5.58, indicating a potential upside of 13.48%. Given Medexus Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Medexus Pharmaceuticals is more favorable than MediPharm Labs.
Medexus Pharmaceuticals has higher revenue and earnings than MediPharm Labs. MediPharm Labs is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Medexus Pharmaceuticals had 20 more articles in the media than MediPharm Labs. MarketBeat recorded 20 mentions for Medexus Pharmaceuticals and 0 mentions for MediPharm Labs. Medexus Pharmaceuticals' average media sentiment score of 0.67 beat MediPharm Labs' score of 0.00 indicating that Medexus Pharmaceuticals is being referred to more favorably in the media.
8.3% of Medexus Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.7% of MediPharm Labs shares are owned by institutional investors. 9.1% of Medexus Pharmaceuticals shares are owned by insiders. Comparatively, 4.5% of MediPharm Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Medexus Pharmaceuticals beats MediPharm Labs on 18 of the 19 factors compared between the two stocks.
Get MediPharm Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for LABS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MediPharm Labs Competitors List
Related Companies and Tools
This page (TSE:LABS) was last updated on 1/26/2025 by MarketBeat.com Staff
